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Abstract
Background: Evidence strongly suggests that spontaneous doublet mutations in normal mouse tissues generally arise from
chronocoordinate events. These chronocoordinate mutations sometimes reflect ‘‘mutation showers’’, which are multiple
chronocoordinate mutations spanning many kilobases. However, little is known about mutagenesis of doublet and
multiplet mutations (domuplets) in human cancer. Lung cancer accounts for about 25% of all cancer deaths. Herein, we
analyze the epidemiology of domuplets in the EGFR and TP53 genes in lung cancer. The EGFR gene is an oncogene in which
doublets are generally driver plus driver mutations, while the TP53 gene is a tumor suppressor gene with a more typical
situation in which doublets derive from a driver and passenger mutation.
Methodology/Principal Findings: EGFR mutations identified by sequencing were collected from 66 published papers and
our updated EGFR mutation database (www.egfr.org). TP53 mutations were collected from IARC version 12 (www-
p53.iarc.fr). For EGFR and TP53 doublets, no clearly significant differences in race, ethnicity, gender and smoking status were
observed. Doublets in the EGFR and TP53 genes in human lung cancer are elevated about eight- and three-fold, respectively,
relative to spontaneous doublets in mouse (6% and 2.3% versus 0.7%).
Conclusions/Significance: Although no one characteristic is definitive, the aggregate properties of doublet and multiplet
mutations in lung cancer are consistent with a subset derived from chronocoordinate events in the EGFR gene: i) the eight
frameshift doublets (present in 0.5% of all patients with EGFR mutations) are clustered and produce a net in-frame change;
ii) about 32% of doublets are very closely spaced (#30 nt); and iii) multiplets contain two or more closely spaced mutations.
TP53 mutations in lung cancer are very closely spaced (#30 nt) in 33% of doublets, and multiplets generally contain two or
more very closely spaced mutations. Work in model systems is necessary to confirm the significance of chronocoordinate
events in lung and other cancers.
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Introduction
Cancer is a heterogeneous, multi-step, complex genetic disease
resulting from accumulated mutations. Cancers generally were
considered to arise by the accumulation of an estimated 5–7
causative mutations[1,2].Recently,however, Vogelsteinand others
have shown in breast and colorectal cancers that individual tumors
accumulate ,90 somatically mutated genes [3]. However, a much
smaller number (estimated to be ,11) are likely to be involved in
tumorigenesis in any given tumor. The accumulation of so many
contributory mutations is hard to explain solely by the frequency of
multiple independent mutation events. The accumulation of
mutations in certain cancers may reflect a mutator phenotype with
globally random mutations [4–6]. Sequential selection offers
another explanation [7,8]. One mutation causes over-replication,
giving rise to a clone, which further over-replicates due to a second
mutation, etc. Recently the existence of mutation showers were
reported, raising the possibility of ‘‘cancer in an instant’’ if scattered
mutation showers occur. Mutation showers were found after
analyses of intragenic doublet mutations revealed that they were
clustered and chronocoordinate [9].
We demonstrated that the majority of doublets in the EGFR
gene have a different mutation pattern relative to singlets and
consist of driver plus driver mutations, due to sequential or
chronocoordinate mutations, putatively followed by functional
selection of two individually sub-optimal mutations [10]. In
addition, acquired second mutations (e.g. T790M) in four EGFR
doublets have been reported after treatment with gefitinib and
erlotinib and associated with drug resistance and disease relapse
[11,12]. In contrast, most TP53 and lacI doublets show driver plus
passenger mutations in lung cancers and in normal Big Blue
mouse tissue, respectively. However, the epidemiology and
mechanisms underlying mutagenesis of doublets and multiple
mutations are unclear.
To elucidate the frequency of doublets and the distinct mutation
pattern and spectrum in the EGFR gene, the epidemiology of
doublet mutations in lung cancer is analyzed and compared to that
of doublets in the TP53 gene. Herein, we find that smoking status,
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occurrence in the EGFR and TP53 genes. The relative frequency
of doublets is higher in human lung cancer than in normal mouse
tissue. The existence of OMIDI pairs (see Terminology and
Abbreviations in Materials and Methods) in EGFR, the high
frequency of allelic versus compound heterozygote doublets, the
high frequency of closely spaced doublets, and the clustering in
multiplets are consistent with chronocoordinate mutations con-
tributing to at least a subset of the EGFR and TP53 doublet and
multiplet mutations found in human lung cancer.
Results
Epidemiology of doublet mutations in the EGFR and
TP53 genes in lung cancer
Analysis by smoking status, gender, and ethnicity does not
reveal a significant difference in doublet frequency in the EGFR
gene (Table 1, Table S1). The average age of patients with singlets
and doublets is similar (61.4611.3 vs 65.8610.3).
The results for the TP53 gene in lung cancer are similar with
one exception. The frequency of TP53 doublets is significantly
higher in Asians than in Caucasians (3.2% vs 1.8%, P=0.03)
(Table 1, Table S2), but this is not significant when corrected for
multiple comparison (six Fisher’s Exact Tests performed for the
EGFR and TP53 genes). Additional data are necessary to evaluate
this point.
Overall, 98/1627 (6.0%) of EGFR mutations and 54/2387
(2.3%) of TP53 mutations in human lung cancers are doublets, a
much higher frequency than that observed in the lacI gene in Big
Blue mice (8-fold and 3-fold, respectively) (Table 2).
Doublets tend to cluster in the EGFR and TP53 genes in
lung cancer: the ‘‘half-life of mutation spacing’’ is 9 bp
and 15 bp, respectively
Spontaneous lacI doublets (0.7% of total mutations) are
clustered with a spacing fitting an exponential distribution and
show a similar mutation pattern to singlets, indicating a
chronocoordinate event [13,14]. Based on the doublet spacing
between two mutations, EGFR doublets can be divided into two
groups: the proximal group (,100 bp, average spacing
22.8624.4-bp) and the distal group (.809 bp, average spacing
12.365.1 kb) (Table S1). Analogous to lacI doublets, a subset
[40% (39/98)] of EGFR doublets occurring in the same exon with
proximal spacing shows an exponential (R
2=0.9979) rather than a
quasi-uniform distribution (Figure S1). Half the doublets have
mutations separated by 9 bp or less (the ‘‘half-life of mutation
spacing’’; see Terminology in Materials and Methods).
The spacing distribution for TP53 doublets in lung cancer
occurring in the same exon (43%, 23/54) also shows proximal
spacing (,86 bp, average 20.2620.9 bp) and fits to an exponential
distribution (R
2=0.979) (Table S2, Figure S1) with a half-life of
mutation spacing of 15 bp. Doublets occurring in different exons
have distal spacing (131–4504 bp, average 1317.961000 bp)
separated by an intron. A similar spacing to that in lung cancer
was found for TP53 doublets within the same exon in breast and
colorectal cancers, with a half-life of mutation spacing of 24 and
16 bp, respectively (Tables S4 and S5).
Thus, about one-third of EGFR and TP53 doublets are highly
clustered (# 30 bp) and all doublets occurring within a single exon
have an inter-mutation spacing that is exponentially distributed
rather than the expected quasi-uniform distribution, consistent
with chronocoordinate events in lacI in normal mouse tissue.
The OMIDI pairs are strong evidence for clustered
chronocoordinate mutations
The great majority of spontaneous human germlime or somatic
mouse MIDIs are OMIDIs (FIX, Big Blue); indeed, about half are
single base deletions [15–18]. In contrast, there is a very low
fraction of OMIDIs (0.26%, 4/1526) and nonsense mutations
(0.13%, 2/1526) in EGFR singlets, consistent with a strong
selection for mutations that alter, rather than delete, function.
Eight of 98 (6%) EGFR doublets contain a pair of frameshift
mutations (OMIDI pairs; see abbreviations in Materials and
Methods). All eight of the OMIDI pairs are closely spaced (Table 3,
Figure S2), with the net result being an in-frame mutation. Given
one OMIDI mutation, a second random mutation 39 to the first
(either IMIDI or OMIDI) will restore reading frame only 1/3 of
the time, and a sub-fraction of that third is still protein truncating
because a nonsense mutation occurs prior to the second mutation.
In total 0.49% of reported EGFR mutations (8/1627) are clustered
OMIDI pairs with no truncation mutation occurring before the
second OMIDI. These eight OMIDI pairs are expected to reside
on the same allele; otherwise, compound heterozygous OMIDI
doublets will lead to two allelic truncations, eliminating all EGFR
gene function. Meanwhile, both of the clustered OMIDIs should
also occur in rapid succession (chronocoordinate mutations) within
Table 1. The epidemiology of EGFR and TP53 doublets versus
singlets
1 in lung cancer.
Singlets Doublets
4
EGFR
2
Non-smoker 296 22 (6.9%)
Smoker 314 12 (3.7%)
NA 916 62
Female 431 58 (11.9%)
Male 289 28 (8.8%)
NA 806 10
Asian 727 77 (9.6%)
Caucasian 104 11 (9.6%)
NA 695 8
Average age 61.4611.3 65.8610.3
TP53
3
Non-smoker 192 2 (1.0%)
Smoker 877 11 (1.2%)
NA 1257 41
Female 382 4 (1.0%)
Male 841 22 (2.5%)
NA 1103 28
Asian 720 24 (3.2%)
Caucasian 1443 26 (1.8%)
NA 163 4
Average age 63.1610.6 62.869.0
1Total number of mutations: EGFR, n=1627; TP53, n=2387.
2The number of singlets, doublets and multiplets in EGFR is 1526, 98 and 5,
respectively
3The number of singlets, doublets and multiplets in TP53 is 2326, 54 and 7,
respectively
4The number and percentage of doublets among the total singlets+doublets in
each category by row.
NA: not available.
doi:10.1371/journal.pone.0003714.t001
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randomly occurring in a proliferation-deficient cell resulting from
a single OMIDI is rare. The remaining 14 deletions (in exons), 9
indels and 3 doublets are all in-frame (IMIDI) mutations (Table 2;
Table S1).
The mutations in the single OMIDI pair reported in the TP53
gene are 2309 bp apart, in different exons (Table S2, ID #
14373), and, unlike the OMIDI pairs in the EGFR gene, do not
together restore the reading frame.
EGFR multiplets are consistent with a singlet and a highly
clustered chronocoordinate second mutation
Four triplets and one quadruplet in EGFR were found at a
frequency of 0.3% (5/1627) of lung cancers with mutations prior
to treatment with tyrosine kinase inhibitor (TKI) (Table 4). It is of
interest that pairs of mutations in each of the triplets and three
mutations within the quadruplet are tightly clustered with
proximal spacing (3–60 bp), similar to doublets in lacI in normal
mouse tissues. The third mutation is located in a different exon
with distal spacing. The data are consistent with sequential
selection of two mutations in which one of the mutations is a
chronocoordinate doublet or triplet.
TP53 multiplets (6 triplets and one quadruplet) also account for
0.3% (7/2387) of total mutations (Table S3). Five multiplets (71%,
5/7) reside in the same exon or two exons, consistent with one
mutation and one chronocoordinate doublet. Seven multiplets had
mutations separated by 15 spacing regions. Of these, six were
highly clustered (#30 nt) and nine were within 100 nucleotides or
less. Eighty percent (16/20) of multiple mutations in breast cancer
and 76% (25/33) in colorectal cancer also reside in one or two
exons (Tables S6, S7).
A comparison of OMIDI pairs and closely spaced doublet and
multiplet mutations in the EGFR and TP53 genes is shown in
Table 5. The frequency of OMIDI pairs in the EGFR gene is
approximately 10-fold greater than in the TP53 gene (and the one
OMIDI pair in the TP53 gene does not result in a net in-frame
mutation), reflecting the more frequent selection of mutations that
alter, rather than delete, EGFR protein function. The frequency of
closely spaced mutations in doublets and multiplets in both genes
is similar.
All characterized EGFR doublets are allelic: a significant
subset of chronocoordinate mutations provides an
alternative explanation
At face value, the allelism data suggests that the driver/driver
mutations in EGFR need to be on the same molecule [10].
However, the existence of a substantial subset of chronocoordinate
mutations provides an alternative explanation. Sixteen heterozy-
gous EGFR doublets from three different studies have been
analyzed by cloning or allele-specific amplification (Table S1)
[10,19,20]. Subsequent sequencing of the products revealed that
all these alleles were either doubly mutated or wild type, indicating
that, in every case, both mutations were located on the same allele.
If the doublet pairs result from independent events, half may be
expected to be compound heterozygotes. The observation of
100% allelism (16/16) vs. zero compound heterozygotes
(p=0.002) may reflect that, functionally, the driver/driver
mutations are required to be on the same molecule even though
the EGFR protein forms dimers [10]. However, the data are also
consistent with 50% chronocoordinate events, putatively during
strand replication or patch repair, and 50% independent
sequential mutations without a requirement that both mutations
be on the same molecule (8 of 8 allelic mutations observed when 4
of 8 are expected at random; p#0.08).
Unfortunately, to our knowledge, allelic analysis has not been
performed on heterozygous TP53 doublets.
Discussion
We present the first analysis of the epidemiology of doublets in
lung cancer. Smoking status, race, ethnicity, gender, and age are
not risk factors for doublet occurrence in lung cancer. The high
frequency of clustered doublets, the exponential distribution of
spacing, the occurrence of in-frame clustered OMIDI pairs, the
allelic nature of doublets, and the clustering of multiplets in EGFR
and TP53 are consistent with a significant minority of chron-
Table 2. A comparison of doublet characteristics among EGFR (lung cancer), LacI (Big Blue) and TP53 (lung cancer).
Parameter EGFR LacI TP53
Frequency
# of doublets 98 51 54
Percentage of mutations that are doublets 6% (98/1627) 0.7% (51/7247) 2.3% (54/2387)
Spectrum
Spectrum of singlets vs. doublets Different (P,0.00001) Similar Similar
# of total nonsense mutations 0.2% (3/1627) 14.2% (1028/7247) 8.9% (212/2387)
# of singlet MIDIs 830 1038 271
% of singlet MIDIs that are IMIDIs 99.5% (826/830) 13.8% (143/1038) 14.8% (40/271)
% of doublets with precise recurrences 46.9% (45/96) 0.0% 0.0%
% of doublets with precise recurrences (3 or more identical events) 38.5% (37/96) 0.0% 0.0%
% of doublets containing at least one mutation seen in at least three doublets 75% (72/96) 2% (1/51) 1.9% (1/54)
# of doublet MIDIs 8 4 1
% of doublet MIDIs comprised of IMIDIs 25% (2/8) 25% (1/4) 0
% of doublet OMIDIs that together result in a net in-frame mutation
1 100% (8/8) 100% (3/3) 0
1An OMIDI pair can result in a net in-frame mutation if the second OMIDI restores the reading frame and no nonsense codon occurs between the first OMIDI andt h e
second OMIDI.
doi:10.1371/journal.pone.0003714.t002
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caveats for each of the above observations (see below).
We demonstrate that doublets are more frequent in the EGFR
and TP53 genes in human cancer than in spontaneous somatic
mutations in normal mouse tissue. Within the constraints of
sample size, doublet frequency does not obviously depend on
smoking status, gender, ethnicity, or age. The TP53 gene is
mutated in about half of all tumors and can be used as a ‘‘mutagen
test,’’ that is, the relative frequencies of the different types of
mutation can be used as an epidemiological tool to explore the
contribution of exogenous mutagens vs. endogenous processes in
breast cancers [21,22]. We hypothesized that the higher mutation
rates expected in smokers would more often produce doublet
mutations. However, there is no significant difference between
smokers and non-smokers, consistent with doublets and multiplets
arising from endogenous processes.
Data are consistent with chronocoordinate mutations
(with caveats)
Several aspects of the data are consistent with a subset of EGFR
and TP53 doublets arising from choronocoordinate events rather
than from hypermutability (random distributed spacing) or
sequential selection. About 32–35% of the doublets found in the
TP53 (35%, 19/54) and EGFR (32%, 31/98) genes are either
OMIDI pairs or highly clustered doublets separated by #30 nt.
However, there are caveats for each inference that must be ruled
out in future work. The main value of the present analysis is to generate
data that constrain our hypotheses and, by Occam’s razor, generate a simple
hypothesis (the subset of chronocoordinate events) consistent with multiple data.
(1) The OMIDI pairs are the best evidence for chronocoordi-
nate mutations. For most genes, the majority of spontaneous
MIDIs are OMIDIs, but in the EGFR gene, OMIDIs are rare,
consistent with the overall selection for altered function rather
than lack of function. It is notable that the eight EGFR doublets
containing OMIDI pairs all have closely spaced mutations that
result in a net in-frame mutation, thus producing an EGFR
protein with potentially altered, rather than absent, function.
However, no experimental evidence of a protein containing one of
these doublet mutations has been demonstrated. The most
reasonable explanation for this occurrence is through chrono-
coordinate mutations that are selected together for altered protein
function. An alternative explanation is that OMIDI pairs might
somehow be sequential, although random mutations within a few
nucleotides in the genome must be extremely unlikely.
(2) The relatively high frequency of clustered doublet mutations
in the EGFR gene is consistent with chronocoordinate mutations.
The exponential distribution of the spacing between the two
mutations in EGFR and TP53 doublets in the same exons
(R
2=.0.98) is highly unlikely by chance.
A simulation was performed previously for each of the TP53
exons 5–9 to test the null hypothesis that the mutations in TP53
doublets are independent events and that the distribution of the
spacing between the two mutations depends only on the spectrum
of mutations in the TP53 gene and the size of the mutation target
[13]. The first mutation of each simulated doublet was drawn
randomly based on the observed distribution of singlet mutations
in a given exon. Using the singlet distribution from the TP53
IARC database (release 8) accounts for bias that may result from
closely spaced hot spots. The second mutation in the doublet was
drawn randomly based on a uniform distribution over the TP53
coding sequence for that exon, since it is likely to be a ‘‘hitchhiker’’
(passenger) mutation, rather than a driver mutation for the tumor.
The mutation spacing in the simulated doublets was compared
with 402 actual TP53 doublets in the IARC database from all
types of cancer. The results demonstrated that two mutations
within doublets are not independent events by statistical
comparison of the observed and expected distributions, and
indicated that more doublets occurred with a mutation spacing of
less than 30 nucleotides than expected by chance (P=0.03, 0.02,
0.0006, and 0.01 for exons 5–8). These results are consistent with
the occurrence of chronocoordinate mutations in the human TP53
gene. An alternate explanation for the clustering of doublets is that
they may represent some as yet unappreciated functional
constraints.
(3) The allelic nature of doublets is consistent with chron-
ocoordinate mutations. Among 98 doublet pairs reported in the
literature, only a few have been analyzed to determine whether
they are present on the same or different alleles. Among 16
doublet pairs tested by cloning or allele-specific amplification, all
16 pairs were found to be present on the same allele. However, for
the remaining doublet pairs, in which cloning or allele-specific
amplification was not performed, the possibility that the mutations
were present on different alleles cannot be ruled out.
(4) The relatively high frequency of multiplets with two or more
clustered mutations and an additional mutation at a distal location
also argues for a chronocoordinate mutational event plus an
independent single mutational event. Again, an alternative
explanation could involve functional constraints on the clustered
mutations.
In aggregate, these data are consistent with a contribution of
clustered chronocoordinate mutations to human cancer. An excess
of doublets or multiplets with a subset of clustered distribution
occurs more frequently than predicted by chance in a wide range
of organisms, including riboviruses, DNA viruses, prokaryotes,
yeast, and eukaryotic cell lines and tissues [23,24].
Data support driver plus passenger TP53 doublets in
lung cancer
About 22% of the second mutations in doublets are expected to
be silent if they are ‘‘passenger’’ mutations, rather than ‘‘driver’’
mutations [25]. In the TP53 doublets, there are five silent and two
intronic nucleotide changes (13%, 7/54), not significantly different
from the 23.5% silent nucleotide changes expected to occur with
random passenger mutations (p=0.46) [26,27]. Silent nucleotide
changes (18%, 4/22) within TP53 multiplets are also close to
23.5%. Together, these data imply that TP53 doublets and
multiplets consist of a driver plus passenger mutation pattern, in
contrast to the driver/driver pattern found in EGFR doublets [10].
Doublet mutations are associated with mutation showers in
mouse [9]. The advent of massively parallel sequencing can
facilitate the analysis of sufficient numbers of samples to define any
doublets and then determine whether these doublets are associated
with mutation showers in cancer. The non-random clustering
mutations in mutation showers should provide more definitive
data for the occurrence of chronocoordinate mutations in human
Table 5. Closely spaced doublets and multiplets detected in
the EGFR and TP53 genes.
EGFR
1 (No.) p53
1 (No.)
OMIDI pairs 0.5% (8) 0.04%(1)
Other doublets (spaced #30 nt) 1.4% (23) 0.8% (18)
Multiplets (at least 1 pair spaced #30 nt) 0.2% (3) 0.2% (4)
1Total number of mutations: EGFR, n=1627; TP53, n=2387.
doi:10.1371/journal.pone.0003714.t005
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Materials and Methods
Terminology and abbreviations
Mutation spectrum. The relative frequencies of mutations
at specific sites.
Mutation pattern. The relative frequencies of different types
of mutations, e.g., C to T transitions vs. T to C transitions.
Singlet. A single mutation identified within a gene [13].
Tandem-base mutation (TBM). A mutation that results in
base changes at adjacent nucleotides [28,29].
Doublet. Two mutations identified within a gene including a
mix of TBM and non-TBM mutations.
Multiplet. Three or more mutations identified within a gene,
excluding the situation in which all mutations are adjacent.
Multiplets can include a mix of TBM and non-TBM mutations.
Domuplets. A mutant that is either a doublet or a multiplet.
Approximately 1% of lacI mutant plaques are domuplets [9].
MIDI. Microinsertion, deletion, or indel; an insertion,
deletion or indel that results in a gain or loss of 1 to 50
nucleotides [10].
IMIDI. In-frame MIDI
OMIDI. Out-of-frame MIDI
Half-life of mutation spacing. From the exponential fit to
the data, the interval of mutation spacing corresponding to the
interval encompassing half of the remaining mutations within the
sample. This is analogous to the half-life of a radioisotope.
Chronocoordinate mutation. Multiple mutations occurring
within the same cell cycle and in rapid succession, typically within
seconds to minutes [13].
Mutation shower. Chronocoordinate multiple mutations
that span multiple kilobases [9].
Silent mutation. A neutral mutation that does not change
protein structure, including synonymous coding region changes. It
is recognized that occasional mutation types overlap, e.g., a silent
mutation may activate a cryptic splice site or may inactivate the
normal splice site if it disrupts the splice donor consensus sequence
[30]. In practice very few such overlaps were found.
Samples and mutational analysis
In order to investigate the mechanism and characteristics of
doublets and multiplets, EGFR mutations identified by sequencing
were collected from 66 published papers and our updated EGFR
mutation database [10,31] (www.egfr.org). TP53 mutations were
collected from IARC version 12 (www-p53.iarc.fr) and excluded
mutations in pulmonary fibrosis and in lung cancer in patients
exposed to smoky coal emissions, radon, mustard gas, asbestos,
heavymetals,andatomicbomb radiation(c-rays). Wealsoexcluded
two papers in which multiple mutations comprised .50% of the
total mutations, most likely due to PCR artifacts, since multiple
mutations generally make up only ,3% of total mutations. TP53
mutations in breast and colorectal cancers also were retrieved and
the spacing distribution of doublets/multiplets was analyzed.
Statistical Analysis
Mutation patterns and other categorical count distributions were
tested for significant differences by the Fisher’s Exact Test or
unordered R6C contingency tables using the ‘‘Fisher-Freeman-
Halton’’ testimplemented by the StatXact statistical analysis software
package (CYTEL Software Corporation, Cambridge, MA).
Supporting Information
Figure S1 A subset of doublets shows proximal spacing and fits
to exponential distribution in the EGFR and p53 genes in lung
cancer. Panel A shows the separation (in base pairs) between the
two mutations in EGFR proximal doublets (n=37). The
separation distances were divided into three groups, with spacings
of 1–41 bp, 42–82 bp, and 83–123 bp, and plotted at the
midpoint of each group (20, 60, and 100, respectively). Separation
is defined here as the number of nucleotides between, but not
including, the two mutations in a doublet. For MIDIs, separation
is defined as the number of nucleotides between, but not including,
the start of the first and second MIDIs. Panel B shows the spacing
(in base pairs) between the two mutations in p53 proximal doublets
(n=23). The separation distances were divided into three groups,
with spacings of 1–31 bp, 32–62 bp, and 63–93 bp, and plotted at
the midpoint of each group (15, 30, and 45, respectively).
Found at: doi:10.1371/journal.pone.0003714.s001 (0.62 MB PPT)
Figure S2 Doublets in the EGFR gene that form OMIDI pairs
The wild type (wt) EGFR sequence in exon 19 from nucleotides
2227 to 2280 is shown. The eight OMIDI pairs in lung cancer are
diagrammed to show the deletions (in magenta), insertions (in
green) and a region that is duplicated (in yellow). Note that two of
the doublets consist of two deletions each, five doublets consist of
one deletion plus an indel, and one doublet has a duplication
(insertion) plus an indel. In each case, the reading frame is restored
(see net deletion).
Found at: doi:10.1371/journal.pone.0003714.s002 (0.03 MB
DOC)
Table S1 Supplementary Table 1
Found at: doi:10.1371/journal.pone.0003714.s003 (0.07 MB
XLS)
Table S2 Supplementary Table 2
Found at: doi:10.1371/journal.pone.0003714.s004 (0.07 MB
XLS)
Table S3 Supplemenatary Table 3
Found at: doi:10.1371/journal.pone.0003714.s005 (0.03 MB
XLS)
Table S4 Supplementary Table 4
Found at: doi:10.1371/journal.pone.0003714.s006 (0.08 MB
XLS)
Table S5 Supplementary Table 5
Found at: doi:10.1371/journal.pone.0003714.s007 (0.11 MB
XLS)
Table S6 Supplementary Table 6
Found at: doi:10.1371/journal.pone.0003714.s008 (0.04 MB
XLS)
Table S7 Supplementary Table 7
Found at: doi:10.1371/journal.pone.0003714.s009 (0.06 MB
XLS)
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